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Abstract
Introduction: Therapeutic vaccination with antigen-specific tolerogenic dendritic cells (tolDC) might become a
future option of individualized therapy for patients with autoimmune diseases. In this study, we tested the
possibility of generating monocyte-derived tolDC from patients with primary Sjögren’s syndrome (pSS). We
analyzed phenotype, cytokine production and ability to suppress Ro/La-specific immune responses.
Methods: Monocyte-derived tolDC from patients with pSS were generated in the presence of dexamethasone,
vitamin D3 and lipopolysaccharide (DexVD3 DC). The phenotype was analyzed by flow cytometry and the cytokine
profile was investigated using a 25-plex Luminex assay and ELISA. The capacity to both stimulate Ro/La-specific T
cells and suppress this response was evaluated by autologous mixed lymphocyte reaction (MLR).
Results: DC generated from patients with pSS had a similar phenotype and cytokine profile to those from healthy
controls. DexVD3 DC from pSS patients induced little antigen-specific T cell proliferation, but DexVD3 DC-primed
lymphocytes successfully suppressed Ro/La-specific T cell responses.
Conclusions: DexVD3 DC presenting Ro/La antigens might be a promising new therapeutic option for patients
with pSS.
Keywords: Sjögren’s syndrome, dendritic cells, immunotherapy, Ro/La-specific T cell suppression
Introduction
Primary Sjögren’s syndrome (pSS) is a chronic autoim-
mune disease, characterized by mononuclear cell infiltra-
tions, preferentially in salivary and lacrimal glands that
lead to xerostomia and keratoconjunctivitis sicca, respec-
tively. Similar to other autoimmune diseases, the under-
standing of the pathogenesis of pSS and its etiology is far
from complete [1]. Most of the patients are females (9:1
female-to-male ratio) and presence of autoantibodies
against SSA (Ro52 and Ro60) and SSB (La) antigens is
observed in 50 to 60% and 30 to 40% of patients with pSS,
respectively [2]. The current therapies mostly alleviate the
symptoms of sicca and focuses on extraglandular manifes-
tations (if present) [3]. The results of clinical trials with
biological treatments showed minimal or no effect in
patients with pSS [4,5]. Therefore, there is an ongoing
need for individualized patient treatment. Therapeutic
vaccination with monocyte-derived tolerogenic dendritic
cells (tolDC) might be a future treatment option.
Dendritic cells are unique cells of the immune system
that are bridging innate and adaptive immunity [6]. They
are responsible for the initiation of immune responses
and are involved in regulation of central and peripheral
tolerance [7,8]. For more than a decade, tolDC have been
studied in animal models of autoimmune diseases, and
they have been shown to both prevent the disease and
treat already established autoimmune conditions [9].
Several protocols for the generation of tolDC have been
developed including modification through pharmacologi-
cal treatment of monocytes with dexamethasone, rapa-
mycin and nuclear factor kappa B (NF-B) inhibitors
[10]. One of the described protocols for the generation of
tolDC includes combined treatment of monocytes with
glucocorticoid dexamethasone, 1a,25-dihydroxyvitamin
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D3 and lipopolysaccharide (LPS) [11]. This protocol per-
forms better than other tolDC treatments in vitro [12]
and has been show to be efficient in a mouse model of
rheumatoid arthritis (RA) [13].
Despite the success of tolDC treatments in mice, the
application of the method in humans is not widely estab-
lished yet. So far, successful generation of tolDC and
induction of antigen-specific T cell hyporesponsiveness
was reported only for RA and multiple sclerosis (MS)
patients [14,15]. In our study we addressed the feasibility
of generating functional tolDC from patients with pSS as
it was previously reported that the monocytes from these
patients are functionally impaired [16].
Materials and methods
Patient material
Blood samples from pSS patients fulfilling the American-
European classification criteria for pSS [17] (n = 12) were
collected at the Department of Rheumatology, Haukeland
University Hospital, Bergen, Norway. The control group
consisted of five gender- and age-matched healthy blood
donors from the Blood Bank at Haukeland University
Hospital, Bergen, Norway. The characteristics of patients
are given in Table 1.
The study was approved by the Ethics Committee at
the University of Bergen (Approval number 242.06) and
all subjects (both patients and healthy blood donors)
signed the informed consent according to the Declaration
of Helsinki.
Generation of dendritic cells
Dendritic cells (DC) were generated from monocytes iso-
lated from fresh blood collected into heparin tubes from
pSS patients and healthy blood donors as described pre-
viously [12]. The autologous peripheral blood mononuc-
lear cells (PBMC) depleted for monocytes (nonadherent
cells, NAC) were cryopreserved in X-VIVO20 medium
with 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich,
St. Louis, MO, USA) and stored at -80°C until further use.
DexVD3 DC were generated by addition of 1 μM dexa-
methasone (Sigma-Aldrich, St. Louis, MO, USA) at day 3
and dexamethasone plus 0.1 nM 1a,25-dihydroxyvitamin
D3 (Enzo Life Sciences, Laussen, Switzerland) at day 6.
Since DMSO was used as a solvent for all compounds the
equivalent amount of DMSO was added to the control
populations (DMSO DC) on days 3 and 6. On day 6, the
cells were either incubated with 1 μg/ml tuberculin puri-
fied protein derivative (PPD, Statens Serum Institut,
Copenhagen, Denmark) or a mixture of recombinant
Ro52, Ro60 and La protein (1 μg/ml each, all from Arotec
Diagnostics, Wellington, New Zealand). DexVD3 DC and
half of the DMSO DC were stimulated with LPS (100 ng/ml,
Sigma-Aldrich, St. Louis, MO, USA) at the time of antigen
supplement. Cells were harvested 24 h after the stimulation.
Flowcytometry
Immunostaining was performed as described previously
[12]. Briefly, after 5 min incubation with Fc receptor
block (Miltenyi, Bergisch Gladbach, Germany) cells were
stained with a titrated amount of antibodies for 10 min
in the dark at room temperature before being washed
and immediately analyzed on a LSRFortessa cytometer
(BD Biosciences, Heidelberg, Germany). All subsequent
analyses were done with FlowJo software (Tree Star,
Ashland, OR, USA). One percent false-positive events
were accepted in the negative controls. The antibodies
used for DC phenotyping were CD1a-PE (HI149),
CD14-FITC (18D11) from ImmunoTools (Friesoythe,
Germany); HLA-DR-Horizon V500 (G46-6), CD83-PE-
CF594 (HB15e) from BD Biosciences (Heidelberg,
Germany); CD38-PerCP-Cy5.5 (HIT2), CD86-Alexa Fluor
647 (IT2.2), CD80-Brilliant Violet 605 (2D10), CD40-PE-
Cy7 (5C3); CCR7-Brilliant Violet 421 (G043H7), all from
BioLegend (San Diego, CA, USA).
Cytokine determination
Cell-free supernatants from DC cultures were stored in
aliquots at -20°C. Production of cytokines, chemokines
and growth factors was analyzed with a Cytokine
Human Magnetic 25-plex panel assay (Life Technolo-
gies, Glasgow, UK) on a Luminex 100 System (Luminex
Corporation, Austin, TX, USA) according to the manu-
facturer’s instructions. Levels of B-cell activating factor
(BAFF) in supernatants were measured with the Quanti-
kine Human BAFF/BLyS ELISA from R&D Systems
(Minneapolis, MN, USA).
T cell stimulatory capacity
To analyze the capacity of the generated DC populations
to induce antigen-specific T cell responses, an autologous
mixed lymphocyte reaction (MLR) was utilized. The
autologous PBMC depleted for monocytes (nonadherent
cells, NAC) were thawed and allowed to rest overnight
before being labeled with CellTrace Violet Cell Prolifera-
tion Kit (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s recommendations. A total of 200,000
CellTrace Violet-labeled NAC were then co-cultured
with 40,000 autologous DC previously incubated with
antigen (PPD or Ro/La). After 5 days the cells were har-
vested, stained for CD4 (CD4-APC, MEM-241, from
ImmunoTools, Friesoythe, Germany) and proliferation
was analyzed on an LSRFortessa flow cytometer. For the
induction of Ro/La-specific T cells, only patients positive
for Ro or La were used.
Suppression experiments
To analyze the suppressive capacity of lymphocytes primed
with the different DC populations (immature DMSO DC,
LPS-stimulated DMSO DC, LPS-stimulated DexVD3 DC),
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autologous NAC of Ro/La autoantibody-positive patients
were thawed and allowed to rest overnight before priming
with tolDC (1:6 DC to NAC ratio) for 5 days. Then the
nonadherent lymphocytes were harvested, washed and
rested for another 5 days. After the rest, these cells were
harvested, washed, counted and labeled using the CellTrace
Violet Cell Proliferation Kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Mature
DMSO DC previously pulsed with Ro and La antigens and
autologous naive NAC (responder cells) were thawed and
allowed to rest overnight. Then the responder cells were
labeled with CFDA-SE (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions to prevent
convergence with DC-primed NAC. Responder cells were
incubated with DC-primed cells and in the presence of
mature DMSO DC (ratio 2:1:0.2). After the co-culture for
5 days the cells were harvested and proliferation was ana-
lyzed on an LSRFortessa flow cytometer.
All co-culture experiments and resting phases were car-
ried out in X-VIVO20 medium supplemented with IL-2
(50 U/ml; ImmunoTools, Friesoythe; Germany).
Statistical analysis
Mann-Whitney U test was used for group-wise statistical
analyses. Significance was set at P < 0.05. All statistical
calculations were done with Prism 5 (GraphPad Software,
Inc., La Jolla, CA, USA).
Results
Monocyte-derived DC from patients with pSS have a
similar phenotype as DC from healthy controls
First, we investigated the phenotype of the three DC
populations generated from patients with pSS in compar-
ison to cells from age- and gender-matched healthy
controls (Figure 1; see Figure S1 in Additional file 1).
Immature DMSO DC in both groups were characterized
by low levels of MHC class II molecules, and lower levels
of co-stimulatory molecules CD80, CD86, CD40, CD83,
and migration markers CD38 and CCR7. Stimulation of
DMSO DC with LPS upregulated the expression of those
molecules (Figure 1). Both immature and mature DMSO
DC expressed relatively high levels of the DC marker
CD1a, and no monocyte-macrophage marker CD14 was
Table 1 Clinical data on patients used in the study
Cohort characteristics
Sjögren’s syndrome Healthy controls
Number n = 12 n = 5
Age in years (mean +/- SD) 50 +/-13 45 +/-7
Range 33-71 34-52
Female:male 12:0 5:0
Time since diagnosis in years (mean +/- SD) 8.5 +/- 4.1
Clinical features
Anti-Ro 10/12
Anti-La 5/12
Both anti-Ro and anti-La 5/12
No anti-Ro and anti-La 2/12
Rheumatoid factor 4/12
Anti-ribonucleoprotein 1/12
Focus score
FS:0 3/12
FS:1 2/12
FS:2 5/12
FS:3 0/12
FS:4 2/12
FS:5 0/12
Treatment
Antimalarial 4/12
Methotrexate 1/12
Extraglandular manifestations 8/12
Hypothyriodism 2/12
Polyarthritis 2/12
Exanthema 2/12
Polyneuropathy 1/12
Pulmonary embolism 1/12
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Figure 1 Monocyte-derived tolDC from patients with pSS have a similar phenotype to tolDC from healthy controls. The percentage of
positive cells or median fluorescence intensity (MFI) is shown. MFI was used when all DC populations showed more than 90 percent positivity.
Each symbol represents an independent sample, n = 9 for DC from patients with pSS (filled circles) and n = 5 for DC from healthy controls
(open squares). Differences between the expression of surface markers are marked with the following: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. The
bars indicate median. DMSO-, immature DC; DMSO+, LPS-stimulated DC; DexVD3+, LPS-stimulated DC generated in the presence of
dexamethasone and 1alpha,25-dihydroxyvitamin D3; pSS, primary Sjögren’s syndrome; tolDC, tolerogenic dendritic cells.
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detected on their surface. DexVD3 DC from patients with
pSS and controls had a semi-mature macrophage-like
phenotype with low CD1a and high CD14 expression,
low MHC class II, CD40, CD80, CD83, CD86, and CCR7.
CD38 was expressed significantly higher on DexVD3 DC
in comparison to mature DMSO DC in both pSS and
controls (P = 0.005 and P = 0.01, respectively). The
results were similar for patients with and without anti-
rheumatic treatment.
DexVD3 DC generated from patients with pSS are
efficient IL-10 producers
Next, the supernatants from DC populations generated
from patients with pSS and healthy controls were ana-
lyzed using a 25-plex Luminex assay (Figure 2). LPS-
stimulated DMSO DC from patients with pSS produced
significantly higher amounts of macrophage inflamma-
tory protein-1a (MIP-1a; CCL3) and IL-8, and signifi-
cantly lower quantities of IFN-g and IL-5 compared to
mature DMSO DC from healthy controls. DexVD3 DC
from patients with pSS produced significantly higher
amounts of the anti-inflammatory cytokine IL-10 in
comparison to both immature and mature DMSO DC.
Those DC also secreted significantly lower amounts of
proinflammatory cytokines IL-12 and TNF-a as well as
chemokine monokine induced by gamma interferon
(MIG; CXCL9) in comparison to mature DMSO DC.
Both mature DMSO DC and DexVD3 DC generated
from pSS patients produced significantly higher quanti-
ties of cytokines and chemokines IL-6, -7, -13, -15, -17,
interferon gamma-induced protein 10 (IP-10; CXCL10),
IL-2R, MIP-1a, MIP-1b (CCL4), monocyte chemotactic
protein-1 (MCP-1; CCL2), IFN-a, RANTES (CCL5;
Figure 2) in comparison to immature DMSO DC gener-
ated from pSS patients. In supernatants of DC generated
from healthy controls similar trends were observed,
however, the differences were not significant. DexVD3
DC from patients with pSS produced significantly higher
amounts of MIP-1a in comparison to DexVD3 DC gen-
erated from healthy controls. The only cytokine that
was produced in higher quantities by all DC populations
generated from healthy controls compared to pSS
patients was IL-2.
None of the generated DC populations produced any
BAFF (data not shown).
Anti-rheumatic treatment did not have an effect on
cytokine and chemokine production of the monocyte-
derived DC populations.
DexVD3 DC-primed NAC from patients with pSS suppress
antigen-specific T cell proliferation
Next, we determined the immunostimulatory capacity of
the three DC populations generated from patients with
pSS using autologous NAC and PPD as a recall antigen.
NAC were labeled with CellTrace Violet and its dilution
was measured after co-culture with PPD-primed DC (for
gating strategy see Figure S2 in Additional file 2). In line
with their phenotype and cytokine production, immature
DMSO DC and DexVD3 DC induced less proliferation
(median 15.3% and 13.7%, respectively) when compared to
LPS-stimulated DMSO DC (median 22.1%) (Figure 3A).
However, the difference did not reach statistical signifi-
cance (P > 0.05).
Then, we evaluated if this was also the case when using
pSS-related autoantigens Ro52, Ro60 and La48. First, we
measured the proliferation levels of autologous NAC
after co-culture with the three DC populations. Similar
to the experiments with PPD as an antigen, LPS-stimu-
lated DMSO DC induced the highest proliferation rate
(up to 37.5%, median 23.4%). DexVD3 DC performed at
similar efficiency as immature DMSO DC (median
16.5% and 13.8%, respectively, P > 0.05) (Figure 3B).
After the co-culture and removal of the DC, the NAC
were rested for 5 days. The cells were then used as effec-
tor cells in order to test their ability to suppress naive
T cell proliferation upon stimulation with mature DMSO
DC loaded with Ro52, Ro60 and La48. Addition of NAC
previously primed with DexVD3 DC to the co-culture
reaction resulted in significantly reduced proliferation of
responder cells when compared to both immature and
mature DMSO DC (Figure 3C; for gating strategy see
Figure S3 in Additional file 3). The results were not
affected by the medication of some of the patients as
similar results were obtained for all patients included.
The supernatants from both, resting NAC and suppres-
sion co-cultures, were analyzed using a 25-plex Luminex
assay. During the resting phase, the NAC previously
primed with mature DMSO DC secreted significantly
higher amounts of TNF-a, IFN-g, RANTES, MIP-1a,
MIP-1b, IL-2R, and -5, when compared to NAC previously
primed with immature DMSO DC and DexVD3 DC
(Figure 4). The IL-12 production by NAC primed with
mature DMSO DC was significantly higher when com-
pared to DexVD3 DC, but not to immature DMSO DC.
Both NAC primed with mature DMSO DC and DexVD3
DC produced higher amounts of IL-6 in comparison to
NAC primed with immature DMSO DC. Furthermore,
NAC primed with DexVD3 DC produced significantly
higher amounts of IFN-a (vs. NAC primed with immature
DMSO DC) and IL-8 (vs. both NAC primed with imma-
ture and mature DMSO DC).
In the supernatants from the suppression co-cultures
with effector cells primed by DexVD3 DC, we detected
significantly higher levels of IL-8 (vs. primed by imma-
ture DMSO DC; Figure 5) and IL-2 (vs. both primed by
immature and mature DMSO DC IL-2R). In addition to
that, in co-cultures with effector cells primed by mature
DMSO DC higher levels of IL-2R and MIG were detected
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Figure 2 Cytokine profile of DexVD3 DC generated from patients with pSS. The cell-free supernatants were collected when harvesting the
DC populations and stored in aliquots at -20°C until analysis. The amount of cytokines and chemokines secreted were analyzed using a 25-plex
bead assay and the concentrations are given in pg/ml. Each symbol represents an independent sample, n = 9 for supernatants from DC from
patients with pSS (filled circles) and n = 3 for supernatants from DC from healthy controls (open squares). GM-CSF and IL-4 were part of the
added cytokines and therefore not included in the analysis. Cytokines and chemokines without significant differences between the groups (IL-1b,
IL-1RA and Eotaxin) are not shown. The bars show the median and the differences between the secreted amounts of cytokines are marked with
the following: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. DMSO-, immature DC; DMSO+, LPS-stimulated DC; DexVD3+, LPS-stimulated DC generated in
the presence of dexamethasone and 1alpha,25-dihydroxyvitamin D3; GM-CSF, granulocyte-macrophage colony-stimulating factor; pSS, primary
Sjögren’s syndrome.
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(Figure 5). The medication of some of the patients did
not influence the results.
Discussion
Our study demonstrates the successful generation of
monocyte-derived tolDC from patients with pSS using
the previously established robust protocol that relies on
the combined effect of dexamethasone, vitamin D3 and
Toll-like receptor 4 (TLR4) ligand LPS [11,12]. DexVD3
DC generated from patients with pSS had a typical
semi-mature phenotype similar to those generated from
healthy controls.
Figure 3 DexVD3 DC primed lymphocytes from patients with pSS suppress antigen-specific T cell proliferation. (A) First, DC from a group
of patients with pSS (n = 4) were pulsed with 1 μg/ml PPD and co-cultured with CellTrace Violet-labeled autologous NAC (1:5 ratio) and the
percentage of proliferated cells was analyzed. (B) Next, this experiment was repeated with another group of patients (n = 4) using a mixture of
Ro52, Ro60 and La (1 μg/ml each). (C) Naïve NAC (responder cells labeled with CFSE) were co-cultured with different DC-primed NAC (effector cells
labeled with CellTrace Violet) in the presence of Ag-loaded mature DMSO DC (ratio 2:1:0.2) for 5 days. CellTrace Violet-positive cells were gated out
and the level of proliferation of CFSE-labeled responder cells was evaluated as the reduction of MFI. The DC population that was used to stimulate
the effector cells is shown on the x-axis. DMSO-, immature DC;, DMSO+, LPS-stimulated DC; DexVD3+, LPS-stimulated DC generated in the
presence of dexamethasone and 1alpha,25-dihydroxyvitamin D3; NAC, nonadherent cells; PPD, purified protein derivative; pSS, primary Sjögren’s
syndrome. Each dot represents one individual experiment, bars indicate median, n = 4 (same patients as in Figure 3B), *P ≤ 0.05.
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Figure 4 NAC previously primed with DexVD3 DC secrete IL-8 during the rest phase. Cytokine and chemokine profiling was performed on
culture supernatants from NAC previously primed with various DC populations generated from pSS patients. The cell-free culture supernatants
were collected after co-culture of DC and NAC and stored in aliquots at -20°C until analysis. The amount of cytokines/chemokines secreted was
analyzed using a 25-plex bead assay and the concentrations are given in pg/ml. The bars show the median, n = 6. The differences between the
secreted amounts of cytokines are marked with the following: *P ≤ 0.05; **P ≤ 0.01. Cytokines and chemokines that showed results below the
detection limit (IL-10, Eotaxin, IL-17, GM-CSF, IL-1b, IL-4) and those that where the differences were not significant are not shown. The DC
population that was used to stimulate NAC is shown on the x-axis. See Figure 1 for definitions. GM-CSF, granulocyte-macrophage colony-
stimulating factor; NAC, nonadherent cells.
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Interestingly, we observed a high expression of CD38
on DexVD3 DC, both from patients with pSS and con-
trols. Under normal conditions, CD38 is highly expressed
on monocytes and when monocytes turn into immature
DC the expression of CD38 decreases [18]. During the
maturation of DC it is upregulated to the same extent as
on monocytes [18]. The significantly increased expression
of CD38 on DexVD3 DC might favor good migratory
capacity of DexVD3 DC, as CD38 is associated with
migration and survival of human DC [19], and might be
an additional indicator of their semi-mature phenotype.
Indeed, in an experimental model of RA, DexVD3 DC
efficiently migrated from the site of injection to lymph
nodes and secondary lymphoid organs [13]. CD38
expression might therefore be useful as a quality control
marker for tolDC [14]. Moreover, high CD38 expression
on DexVD3 DC might be involved in the induction of
type 1 regulatory T cells (Tr1 cells) by these DC [13] as
CD38 is a ligand for CD31, a molecule that is required
for T cell tolerance [20].
Similar to our previous study with DC generated from
healthy blood donors, the DexVD3 DC generated from
pSS patients produced the highest amounts of IL-10 and
little IL-12 [12]. In contrast to our previous observation
on DC generated from healthy blood donors, the
DexVD3 DC from pSS patients secreted increased
amounts of IL-6, -7, -13, -15, -17, IP-10, IL-2R, MIP-1a,
MIP-1b, MCP-1, IFN-a, TNF-a and RANTES compared
to immature DMSO DC. Furthermore, the quantities of
these cytokines were even higher than those produced
by mature DMSO DC from pSS patients, although the
differences were not significant. The observed increased
Figure 5 IL-2 and IL-8 are produced in larger quantities in suppression experiments with effector cells primed by DexVD3 DC. The
supernatants were collected before the FACS analysis of proliferation of the responder cells and stored in aliquots at -20°C until analysis. The
amount of cytokines/chemokines secreted were analyzed using a 25-plex bead assay and the concentrations are given in pg/ml. Cytokines and
chemokines that showed results below the detection limit (IL-1b, IL-4, Eotaxin, GM-CSF, IL-17), and those that where the differences were not
significant, are not shown. The bars indicate the median, n = 4. The differences between the secreted amounts of cytokines are marked with the
following: *P ≤ 0.05.
Volchenkov et al. Arthritis Research & Therapy 2013, 15:R114
http://arthritis-research.com/content/15/5/R114
Page 9 of 12
production of proinflammatory cytokines and chemo-
kines in DC from pSS patients might be due to systemic
inflammation and activation of compensatory mechan-
isms. However, these DC were still able to induce anti-
gen-specific suppressor cells, indicating a dominant role
for IL-10.
It has previously been reported that monocytes from
pSS patients produced high levels of IL-6 and BAFF [16].
We were, therefore, interested to see if this would be car-
ried over to the monocyte-derived DC from pSS patients.
Although we observed significant differences in IL-6 pro-
duction between different groups of DC generated from
pSS patients, there were no differences in IL-6 production
between DC generated from pSS patients and healthy con-
trols. It was reported previously that IL-6 is important in
T helper 17 (Th17) cell differentiation, as IL-6 influences
the balance between regulatory T cells (Treg) and Th17
cells in favor of inflammation [21-24]. However, in most
of these studies, the transcription factor FoxP3 was used
to define Tregs, while numerous studies have demon-
strated that this is not a suitable marker for cells with reg-
ulatory functions in humans [25-27]. In addition, the
vaccination with DexVD3 DC in collagen-induced arthritis
was associated with a reduction of Th17 cells [13]. There-
fore, the increase of IL-6 production by DexVD3 DC
observed in our study might be compensated for by their
tolerogenic effects. Moreover, no BAFF was detected in
supernatants from monocyte-derived DC. Therefore, we
believe that tolDC generated from monocytes of pSS
patients do not have the same functional impairment as
monocytes. However, the previously mentioned study by
Yoshimoto et al. used an in-house ELISA for the detection
of BAFF with a higher sensitivity in comparison to com-
mercially available ELISAs [16].
One of the important considerations for immunother-
apy with tolDC is the ability of tolDC to overcome the
immunogenic DC that initiate immune response toward
self-antigens in the patients. In our study, DexVD3 DC-
primed NAC were able to suppress stimulation of naïve
T cells in the presence of fully matured DC loaded with
pSS-related autoantigens Ro52, Ro60 and La. We have
previously shown that DexVD3 DC induce both type 1 T
regulatory cells (Tr1) and B regulatory cells (Breg) [12]. It
seems, therefore, likely that the observed suppression
described here is most likely mediated by Tr1 and Breg
cells [12,13]. The Tr1 cells utilize several mechanisms to
perform their regulatory function. These include produc-
tion of inhibitory cytokines, release of proteases (Gran-
zyme A) and cell-to-cell contact [28]. The latter
mechanisms might be used by DexVD3 DC-induced Tr1
cells, as we observed no increase in anti-inflammatory
cytokines in the supernatants from neither resting NAC
nor suppression co-cultures. However, our results are
limited by the small sample size in our suppression
experiments as it was not possible to include all patients
in these experiments. The number of PBMC we were
able to isolate from the limited amounts of peripheral
blood from each patient restricted the number of experi-
ments we could perform with cells from each patient.
Interestingly, resting NAC primed by DexVD3 DC
secreted considerably higher amounts of IL-8 in our
experiments. A similar increase of IL-8 production was
observed during the suppression experiments with NAC
primed by DexVD3 DC. IL-8 is a proinflammatory cyto-
kine that is involved in T cell chemotaxis [29,30]. How-
ever, it is also a signature cytokine for the Treg cell line
HOZOT-4, established from human umbilical cord blood
[31,32] and can be produced by FoxP3+ Treg [33]. Since
we previously showed that the DexVD3 DC induce Tr1
cells and not FoxP3+ Treg [12], it would be interesting to
see whether IL-8 is involved in regulatory function of Tr1.
Although promising, our results are limited by the
fact that autoantibodies against Ro and La are not pre-
sent in all patients and different patients might have
different epitopes to which their immune systems
react. Indeed, in patients without Ro and La autoanti-
bodies, we did not observe a significant suppression of
proliferation by DexVD3 DC-primed effector cells
(data not shown). In RA patients, it was proposed to
use synovial fluid as an autologous source of autoanti-
gens [34], but for pSS such a source of disease-specific
autologous autoantigens has not yet been found.
Therefore, GMP-compatible recombinant proteins for
large-scale pilot studies or preclinical trials have to be
produced. The time of application of a tolDC vaccine
to pSS patients is another complicated issue. Usually, it
takes several years to establish a diagnosis and often at
this time the damage to salivary glands is irreversible
[1]. On the other hand, although some studies have
found associations between the degree of destruction
and loss of function [35-37], at the patient level there
is not necessarily such a correlation.
Conclusions
In summary, this is the first study demonstrating the suc-
cessful generation of Ro/La-loaded tolDC from patients
with pSS able to efficiently induce antigen-specific sup-
pressive immune reactions. As the described protocol can
easily be adjusted to be GMP compatible [14], we believe
that tolDC might be a potentially favourable treatment
option for patients with pSS with known antibody
specificity.
Additional material
Additional file 1: Figure S1. DexVD3 DC have a semi-mature
macrophage-like phenotype. The DC were gated based on forward
and side scatter dot plots and the expression of surface markers was
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analyzed. Each histogram shows the negative control (red), immature
DMSO DC (blue), mature DMSO DC (orange) and DexVD3 DC (green).
Additional file 2: Figure S2. Gating strategy for the analysis of T cell
proliferation after priming with various DC groups. The top left dot
plot depicts cells in a live gate based on forward scatter and side scatter,
the top right dot plot depicts gating on CD4+ and CD8+ T cells. The
bottom left histogram represents proliferation of CD8+ T cells and the
bottom right histogram shows the proliferation of CD4+ T cells.
Additional file 3: Figure S3. Gating strategy for the analysis of the
suppressive capacity of lymphocytes primed with various tolDC
populations. Naïve responder cells were labeled with CFSE and tolDC-
primed NAC were labeled with CellTrace Violet. This allowed exclusive
gating on CellTrace Violet-negative cells and further analysis of
proliferation of CFSE-labeled responder cells. The top left dot plot depicts
cells in a live gate based on forward scatter and side scatter, the top
right histogram depicts gating on CellTrace Violet-negative cells. The
bottom histogram shows proliferation of CFSE-labeled CellTrace Violet-
negative responder cells after co-culture with differently primed NAC.
MFI values of proliferated responder cells and tolDC populations that
were used to stimulate effector cells are shown in the histograms
legend. MFI, median fluorescence intensity; NAC, nonadherent cells;
tolDC, tolerogenic dendritic cells.
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